<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:DengXian;
	panose-1:2 1 6 0 3 1 1 1 1 1;}
@font-face
	{font-family:Aptos;}
@font-face
	{font-family:Consolas;
	panose-1:2 11 6 9 2 2 4 3 2 4;}
@font-face
	{font-family:"\@DengXian";
	panose-1:2 1 6 0 3 1 1 1 1 1;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:115%;
	font-size:12.0pt;
	font-family:"Aptos",sans-serif;}
a:link, span.MsoHyperlink
	{color:#467886;
	text-decoration:underline;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:.5in;
	line-height:115%;
	font-size:12.0pt;
	font-family:"Aptos",sans-serif;}
p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParagraphCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:115%;
	font-size:12.0pt;
	font-family:"Aptos",sans-serif;}
p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListParagraphCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	line-height:115%;
	font-size:12.0pt;
	font-family:"Aptos",sans-serif;}
p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagraphCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:.5in;
	line-height:115%;
	font-size:12.0pt;
	font-family:"Aptos",sans-serif;}
span.apple-converted-space
	{mso-style-name:apple-converted-space;}
.MsoChpDefault
	{font-size:12.0pt;
	font-family:"Aptos",sans-serif;}
.MsoPapDefault
	{margin-bottom:8.0pt;
	line-height:115%;}
@page WordSection1
	{size:11.0in 8.5in;
	margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
	{page:WordSection1;}
@page WordSection2
	{size:8.5in 11.0in;
	margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection2
	{page:WordSection2;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-US link="#467886" vlink="#96607D" style='word-wrap:break-word'>

<div class=WordSection1>

<p class=MsoNormal align=center style='text-align:center'><b><span
style='font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif'>Summary
of sharing of data and code for Gilbert et al. “Immune&nbsp;Correlates Analysis
of&nbsp;the&nbsp;VAT00008&nbsp;Efficacy Trial of Bivalent
(D614&#8201;+&#8201;B.1.351)
SARS-CoV-2&nbsp;Recombinant&nbsp;Protein&nbsp;Variant&nbsp;Vaccine with AS03&nbsp;Adjuvant”</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span
style='font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif'>Youyi
Fong, Peter Gilbert, Lindsay Carpp</span></b></p>

<p class=MsoNormal align=center style='text-align:center'><b><span
style='font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif'>December
12, 2025</span></b></p>

<p class=MsoNormal><span style='font-size:11.0pt;line-height:115%;font-family:
"Arial",sans-serif'>&nbsp;</span></p>

<p class=MsoNormal><span style='font-size:11.0pt;line-height:115%;font-family:
"Arial",sans-serif'>All analyses use code in this release if not otherwise
specified:<br>
https://github.com/CoVPN/correlates_reporting2/archive/refs/tags/sanofi_stage2_correlates_R40.zip
</span></p>

<p class=MsoNormal><span style='font-size:11.0pt;line-height:115%;font-family:
"Arial",sans-serif'>All analyses are based on the analysis-ready data file vat08_combined_data_processed_20250417.csv.
Path to the data file should be updated in config.yml in the data_cleaned field
uder vat08_combined if not otherwise specified.</span></p>

<p class=MsoNormal><span style='font-size:11.0pt;line-height:115%;font-family:
"Arial",sans-serif'>&nbsp;</span></p>

<p class=MsoNormal><b><span style='font-size:11.0pt;line-height:115%;
font-family:"Arial",sans-serif'>Notes:</span></b></p>

<p class=MsoNormal><span lang=EN-CA style='font-size:11.0pt;line-height:115%;
font-family:"Arial",sans-serif'>Level 1 reproducibility test: A report has been
generated by someone other than the module’s author in an existing clone of the
repo. </span></p>

<p class=MsoNormal><span lang=EN-CA style='font-size:11.0pt;line-height:115%;
font-family:"Arial",sans-serif'>Level 2 reproducibility test: A report has been
generated following README.md in a new directory on a SCHARP server.</span></p>

<p class=MsoNormal><span lang=EN-CA style='font-size:11.0pt;line-height:115%;
font-family:"Arial",sans-serif'>&nbsp;</span></p>

<p class=MsoNormal><b><span style='font-size:11.0pt;line-height:115%;
font-family:"Arial",sans-serif'>Table and Figure captions, code on Github, and
statistical reports on network drives</span></b></p>

<p class=MsoNormal><b><span style='font-size:11.0pt;line-height:115%;
font-family:"Arial",sans-serif'>&nbsp;</span></b></p>

<p class=MsoNormal style='background:white'><span lang=EN-CA style='font-size:
11.0pt;line-height:115%;font-family:"Arial",sans-serif;color:black'>Table 1. </span><span
style='font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
color:black'>bAb-IgG Spike and nAb-ID50 antibody </span><span lang=EN-CA
style='font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
color:black'>marker seroresponse frequencies (when applicable) by COVID-19
outcome status, geometric means (GMs) by COVID-19 outcome status, and their
comparisons between non-cases and cases. Analysis based </span><span
lang=EN-CA style='font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
color:black'>on eligible COVID-19 cases<sup>1</sup> and non-cases<sup>2</sup> from
the non-naïve Per-Protocol Case-Cohort set. A) Placebo group; B) Vaccine group.
</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-CA style='font-size:
11.0pt;line-height:115%;font-family:"Arial",sans-serif;color:black'>Statistical
report:</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-CA style='font-size:
11.0pt;line-height:115%;font-family:"Arial",sans-serif;color:black'>T:\covpn\p3005\analysis\correlates\Part_A_Blinded_Phase_Data\reports\covpn_correlates_cor_tabular_vat08_combined_20250520.pdf</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-CA style='font-size:
11.0pt;line-height:115%;font-family:"Arial",sans-serif;color:black'>To
reproduce this report, follow instructions at https://github.com/CoVPN/correlates_reporting2/tree/master/cor_tabular/README.md#sanofi_stage2_correlates
(level 1 reproducibility test passed)</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-CA style='font-size:
11.0pt;line-height:115%;font-family:"Arial",sans-serif;color:black'>Collage
mapping</span></p>

<p class=MsoListParagraph style='text-indent:-.25in;background:white'><span
lang=EN-CA style='font-size:11.0pt;line-height:115%;font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-CA style='font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
color:black'>Data were extracted from pp. 75 (Table 2.57), 78 (Table 2.60), 96
(Table 2.78), and 107+108 (Table 2.84) of the report </span></p>

<p class=MsoNormal style='background:white'><span lang=EN-CA style='font-size:
11.0pt;line-height:115%;font-family:"Arial",sans-serif'>&nbsp;</span></p>

<p class=MsoNormal style='line-height:107%'><span style='font-size:11.0pt;
line-height:107%;font-family:"Arial",sans-serif'>Table&nbsp;2. Mediation effect
estimates with 95% confidence intervals (CIs) for Day 43 antibody marker
mediation of Omicron COVID-19 through 150 days post dose 2 for the non-naïve
Per-Protocol Analysis Set. FR = fold-rise. c.r. = cross-reactivity.</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-CA style='font-size:
11.0pt;line-height:115%;font-family:"Arial",sans-serif;color:black'>Statistical
output:</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-CA style='font-size:
11.0pt;line-height:115%;font-family:"Arial",sans-serif;color:black'>T:\covpn\p3005\analysis\correlates\Part_A_Blinded_Phase_Data\reports\MediationResults</span><span
style='font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
color:black'>\</span><span lang=EN-CA style='font-size:11.0pt;line-height:115%;
font-family:"Arial",sans-serif;color:black'>sanofi_Day43_20250617.csv</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-CA style='font-size:
11.0pt;line-height:115%;font-family:"Arial",sans-serif;color:black'>T:\covpn\p3005\analysis\correlates\Part_A_Blinded_Phase_Data\reports\MediationResults\sanofi_FR_20250617.csv</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-CA style='font-size:
11.0pt;line-height:115%;font-family:"Arial",sans-serif;color:black'>To
reproduce this report, follow instructions at </span><span style='color:black'><a
href="https://github.com/CoVPN/correlates_reporting2/tree/master/cop_mediation/sanofi_stage2"><span
lang=EN-CA style='font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif'>https://github.com/CoVPN/correlates_reporting2/tree/master/cop_mediation/sanofi_stage2</span></a></span><span
style='font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
color:black'> <span lang=EN-CA>(level 1 reproducibility test passed)</span></span></p>

<p class=MsoNormal style='background:white'><span lang=EN-CA style='font-size:
11.0pt;line-height:115%;font-family:"Arial",sans-serif;color:black'>No collage mapping
needed</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-CA style='font-size:
11.0pt;line-height:115%;font-family:"Arial",sans-serif'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-CA style='font-size:
11.0pt;line-height:115%;font-family:"Arial",sans-serif;color:black'>Figure 1.</span><span
class=apple-converted-space><span style='font-size:11.0pt;line-height:115%;
font-family:"Arial",sans-serif;color:black'>&nbsp;</span></span><span
style='font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
color:black'>(A) Cumulative incidence of Omicron COVID-19 by treatment arm for
the SARS-CoV-2 naïve cohort; (B) Cumulative incidence of Omicron COVID-19 by
treatment arm for the SARS-CoV-2 non-naïve cohort; (C) Cumulative
incidence-based vaccine efficacy (VE) against Omicron COVID-19 for the
SARS-CoV-2 non-naïve cohort; (D) Instantaneous smoothed hazard-based VE against
Omicron COVID-19 for the SARS-CoV-2 non-naïve cohort</span><span
style='font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
color:black'>. </span><span style='font-size:11.0pt;line-height:115%;
font-family:"Arial",sans-serif;color:black'> Analyses are based on the
Per-Protocol </span><span style='font-size:11.0pt;line-height:115%;font-family:
"Arial",sans-serif;color:black'>Analysis</span><span style='font-size:11.0pt;
line-height:115%;font-family:"Arial",sans-serif;color:black'> </span><span
style='font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
color:black'>Set and include endpoints &#8805; 14 days post D22 through 360
(245) days post D22 for the cumulative (instantaneous) VE analyses. Shaded
regions indicate 95% pointwise confidence intervals. </span></p>

<p class=MsoNormal style='background:white'><span style='font-size:11.0pt;
line-height:115%;font-family:"Arial",sans-serif;color:black'>Statistical reports:
</span></p>

<p class=MsoNormal style='background:white'><span style='font-size:11.0pt;
line-height:115%;font-family:"Arial",sans-serif;color:black'>T:\covpn\p3005\analysis\correlates\Part_A_Blinded_Phase_Data\reports\OverallVaccineEfficacyOverTime\cumVE_nonnaive.pdf</span></p>

<p class=MsoNormal style='background:white'><span style='font-size:11.0pt;
line-height:115%;font-family:"Arial",sans-serif;color:black'>T:\covpn\p3005\analysis\correlates\Part_A_Blinded_Phase_Data\reports\OverallVaccineEfficacyOverTime\smoothHazVE_nonnaive.pdf</span></p>

<p class=MsoNormal style='background:white'><span style='font-size:11.0pt;
line-height:115%;font-family:"Arial",sans-serif;color:black'>T:\covpn\p3005\analysis\correlates\Part_A_Blinded_Phase_Data\reports\OverallVaccineEfficacyOverTime\stage2_pp_naivecumInc.pdf</span></p>

<p class=MsoNormal style='background:white'><span style='font-size:11.0pt;
line-height:115%;font-family:"Arial",sans-serif;color:black'>T:\covpn\p3005\analysis\correlates\Part_A_Blinded_Phase_Data\reports\OverallVaccineEfficacyOverTime\</span><span
style='color:black'> </span><span style='font-size:11.0pt;line-height:115%;
font-family:"Arial",sans-serif;color:black'>stage2_pp_nonnaivecumInc.pdf</span></p>

<p class=MsoNormal style='background:white'><span style='font-size:11.0pt;
line-height:115%;font-family:"Arial",sans-serif;color:black'>To reproduce this
report, follow the instructions at https://github.com/CoVPN/correlates_reporting2/tree/master/cumulative_incidence/vat08_bivalent
</span><span lang=EN-CA style='font-size:11.0pt;line-height:115%;font-family:
"Arial",sans-serif;color:black'>(level 1 reproducibility test passed)</span></p>

<p class=MsoNormal style='background:white'><span style='font-size:11.0pt;
line-height:115%;font-family:"Arial",sans-serif;color:black'>No collage mapping
needed</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-CA style='font-size:
11.0pt;line-height:115%;font-family:"Arial",sans-serif;color:black'>                                                            </span></p>

<p class=MsoNormal><span style='font-size:11.0pt;line-height:115%;font-family:
"Arial",sans-serif;color:black'>Figure 2. bAb-IgG Spike and nAb-ID50 antibody
marker </span><span lang=EN-CA style='font-size:11.0pt;line-height:115%;
font-family:"Arial",sans-serif'>levels</span><span style='font-size:11.0pt;
line-height:115%;font-family:"Arial",sans-serif;color:black'> by COVID-19
outcome status. Data points are from</span><span style='font-size:11.0pt;
line-height:115%;font-family:"Arial",sans-serif'> <span style='color:black'>eligible
COVID-19 cases and non-cases in the </span></span><span lang=EN-CA
style='font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif'>non-naïve
</span><span style='font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
color:black'>Per-Protocol Case-Cohort set, except that a </span><span
style='font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif'>Per-Protocol
Analysis Set (PPAS) modified non-naïve (instead of whole non-naïve) Random
Immunogenicity Subset (RIS) was used for plotting. This “PPAS modified
non-naïve RIS” is used due to the fact that the PPAS non-naïve RIS largely
oversampled the PPAS subgroup that was D01 anti-Spike positive and negative on
all D01 and D22 tests for anti-N and for RNA PCR (referred to as the “S+ only”
subgroup), which would make the plots misleading. The PPAS modified non-naïve
RIS is the portion of the non-naïve RIS remaining after deleting a random
sample of the PPAS S+only non-naive RIS selected to make the fraction of the
PPAS non-naïve RIS that are PPAS S+only non-naïve RIS equal to the fraction of
the PPAS non-naïve that are PPAS S+only non-naïve (see SAP Section 1). </span><span
style='font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
color:black'>The plots show (A-F) D43 levels in the placebo group; (G-L) D43
levels in the vaccine group; (M-R) fold-rise (D43/D01) in the vaccine group,
for (A, G, M) bAb-IgG Spike Index; (B, H, N) bAb-IgG Spike Beta; (C, I, O)
bAb-IgG Spike Omicron; (D, J, P) nAb-ID50 Reference; (E, K, Q) nAb-ID50 Beta;
(F, L, R) nAb-ID50 BA.1. The violin plots contain interior box plots with upper
and lower horizontal edges representing the 25<sup>th</sup> and 75<sup>th</sup>
percentiles of antibody level and middle line representing the 50<sup>th</sup>
percentile. The vertical bars represent the distance from the 25<sup>th</sup>
(or 75<sup>th</sup>) percentile of antibody level and the minimum (or maximum)
antibody level within the 25<sup>th</sup> (or 75<sup>th</sup>) percentile of
antibody level minus (or plus) 1.5 times the interquartile range. Each side
shows a rotated probability density (estimated by a kernel density estimator
with a default Gaussian kernel) of the data. Cases were Omicron COVID-19
endpoints &#8805; 7 days post D43 through 150 days post D22. Non-cases were
Per-Protocol Analysis Set participants with no evidence of SARS-CoV-2 infection
(i.e., never tested nucleic acid amplification/PCR positive) after D01 up to
the date by which the last enrolled participant reached 150 days post D22
(2022-07-24). The bAb-IgG Spike Index concentrations reported here in AU/ml can
be converted to international units (BAU/ml) by multiplying by the conversion
factor 0.009, and the nAb-ID50 Reference titers reported here can be converted
to international units (IU50/ml) by multiplying by the conversion factor
0.0653.  bAb-IgG Spike, anti-Spike IgG binding antibody concentration; LLOQ,
lower limit of quantitation; LOD, limit of detection; nAb-ID50, 50% inhibitory
serum dilution neutralizing antibody titer; ULOQ, upper limit of </span><span
style='font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
color:black'>quantitation</span><span style='font-size:11.0pt;line-height:115%;
font-family:"Arial",sans-serif;color:black'>. </span></p>

<p class=MsoNormal style='background:white'><span lang=EN-CA style='font-size:
11.0pt;line-height:115%;font-family:"Arial",sans-serif;color:black'>Statistical
report:</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-CA style='font-size:
11.0pt;line-height:115%;font-family:"Arial",sans-serif;color:black'>T:\covpn\p3005\analysis\correlates\Part_A_Blinded_Phase_Data\reports\covpn_correlates_cor_graphical_vat08_combined_stage2_20250422.pdf</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-CA style='font-size:
11.0pt;line-height:115%;font-family:"Arial",sans-serif;color:black'>To
reproduce this report, follow instructions at </span><span style='color:black'><a
href="https://github.com/CoVPN/correlates_reporting2/blob/master/cor_graphical/README.md#sanofi-stage2-correlates"><span
lang=EN-CA style='font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif'>https://github.com/CoVPN/correlates_reporting2/blob/master/cor_graphical/README.md#sanofi-stage2-correlates</span></a></span><span
style='font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
color:black'> <span lang=EN-CA>(level 1 reproducibility test passed)</span></span></p>

<p class=MsoNormal style='background:white'><span lang=EN-CA style='font-size:
11.0pt;line-height:115%;font-family:"Arial",sans-serif;color:black'>Collage
mapping </span></p>

<p class=MsoListParagraphCxSpFirst style='text-indent:-.25in;background:white'><span
style='font-size:11.0pt;line-height:115%;font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
style='font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
color:black'>Panels A, B, C: extracted from page 30 (Figure 2.16)</span></p>

<p class=MsoListParagraphCxSpMiddle style='text-indent:-.25in;background:white'><span
style='font-size:11.0pt;line-height:115%;font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
style='font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
color:black'>Panels D, E, F: extracted from page 20 (Figure 2.6)</span></p>

<p class=MsoListParagraphCxSpMiddle style='text-indent:-.25in;background:white'><span
style='font-size:11.0pt;line-height:115%;font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
style='font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
color:black'>Panels G, H, I: extracted from page 30 (Figure 2.16)</span></p>

<p class=MsoListParagraphCxSpMiddle style='text-indent:-.25in;background:white'><span
style='font-size:11.0pt;line-height:115%;font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
style='font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
color:black'>Panels J, K, L: extracted from page 20 (Figure 2.6)</span></p>

<p class=MsoListParagraphCxSpMiddle style='text-indent:-.25in;background:white'><span
style='font-size:11.0pt;line-height:115%;font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
style='font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
color:black'>Panels M, N, O: extracted from page 34 (Figure 2.20)</span></p>

<p class=MsoListParagraphCxSpMiddle style='text-indent:-.25in;background:white'><span
style='font-size:11.0pt;line-height:115%;font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
style='font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
color:black'>Panels P, Q, R: extracted from page 24 (Figure 2.10)</span></p>

<p class=MsoListParagraphCxSpLast style='text-indent:-.25in;background:white'><span
style='font-size:11.0pt;line-height:115%;font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
style='font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
color:black'>For panels A-L, Ns and positive response frequencies were removed.
</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-CA style='font-size:
11.0pt;line-height:115%;font-family:"Arial",sans-serif'>&nbsp;</span></p>

<p class=MsoNormal><span style='font-size:11.0pt;line-height:115%;font-family:
"Arial",sans-serif;color:black'>Figure 3. Covariate-adjusted hazard ratios
(HRs) of Omicron COVID-19 per 10-fold increase in the designated immune marker
[A, B, C, D: D43 level; E, F: fold/rise (D43/D01)] in non-naïve per-protocol A,
B) placebo recipients or C, D, E, F) vaccine recipients. HRs were estimated
using inverse probability sampling weighted Cox regression models; 95%
confidence intervals (CIs) and Wald-based p-values are shown. Analyses adjusted
for baseline risk score, sex, geographic region, and FOI score. bAb-IgG Spike, anti-Spike
IgG binding antibody concentration; nAb-ID50, 50% inhibitory serum dilution
neutralizing antibody titer.</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-CA style='font-size:
11.0pt;line-height:115%;font-family:"Arial",sans-serif;color:black'>Statistical
report:</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-CA style='font-size:
11.0pt;line-height:115%;font-family:"Arial",sans-serif;color:black'>T:\covpn\p3005\analysis\correlates\Part_A_Blinded_Phase_Data\reports\covpn_correlates_cor_coxph_vat08_stage2_prev_infected_20250321.pdf</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-CA style='font-size:
11.0pt;line-height:115%;font-family:"Arial",sans-serif;color:black'>To
reproduce this report, follow instructions at </span><span style='color:black'><a
href="https://github.com/CoVPN/correlates_reporting2/blob/master/cor_coxph/README.md#sanofi-stage-2-correlates-manuscript"><span
lang=EN-CA style='font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif'>https://github.com/CoVPN/correlates_reporting2/blob/master/cor_coxph/README.md#sanofi-stage-2-correlates-manuscript</span></a></span><span
style='font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
color:black'>  <span lang=EN-CA>(level 2 reproducibility test passed) </span></span></p>

<p class=MsoNormal style='background:white'><span lang=EN-CA style='font-size:
11.0pt;line-height:115%;font-family:"Arial",sans-serif;color:black'>Collage
mapping</span></p>

<p class=MsoListParagraphCxSpFirst style='text-indent:-.25in;background:white'><span
lang=EN-CA style='font-size:11.0pt;line-height:115%;font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-CA style='font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
color:black'>Panel A: from page 79 (Figure 3.58)</span></p>

<p class=MsoListParagraphCxSpMiddle style='text-indent:-.25in;background:white'><span
lang=EN-CA style='font-size:11.0pt;line-height:115%;font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-CA style='font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
color:black'>Panel B: from page 92 (Figure 3.69)</span></p>

<p class=MsoListParagraphCxSpMiddle style='text-indent:-.25in;background:white'><span
lang=EN-CA style='font-size:11.0pt;line-height:115%;font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-CA style='font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
color:black'>Panel C: from page 17 (Figure 3.1)</span></p>

<p class=MsoListParagraphCxSpMiddle style='text-indent:-.25in;background:white'><span
lang=EN-CA style='font-size:11.0pt;line-height:115%;font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-CA style='font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
color:black'>Panel D: from page 53 (Figure 3.34)</span></p>

<p class=MsoListParagraphCxSpMiddle style='text-indent:-.25in;background:white'><span
lang=EN-CA style='font-size:11.0pt;line-height:115%;font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-CA style='font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
color:black'>Panel E: from page 21 (Figure 3.5)</span></p>

<p class=MsoListParagraphCxSpLast style='text-indent:-.25in;background:white'><span
lang=EN-CA style='font-size:11.0pt;line-height:115%;font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-CA style='font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
color:black'>Panel F: from page 57 (Figure 3.38)</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-CA style='font-size:
11.0pt;line-height:115%;font-family:"Arial",sans-serif'>&nbsp;</span></p>

<p class=MsoNormal><span style='font-size:11.0pt;line-height:115%;font-family:
"Arial",sans-serif;color:black'>Figure 4. Vaccine efficacy against Omicron COVID-19
through 124 days </span><span style='font-size:11.0pt;line-height:115%;
font-family:"Arial",sans-serif;color:black'>post </span><span style='font-size:
11.0pt;line-height:115%;font-family:"Arial",sans-serif;color:black'>D43 for
non-naïve per-protocol vaccine recipients with A, B) D43 marker level above a
threshold or C, D) D43/D01 marker fold-rise above a threshold [A, C) bAb-IgG
Spike Omicron concentration; B, D) nAb-ID50 BA.1 titer] vs. the whole non-naïve
per-protocol placebo arm. Vaccine efficacy is one minus the covariate-adjusted
thresholded cumulative incidence in non-naïve per-protocol vaccine recipients
divided by the covariate-adjusted cumulative incidence in non-naïve pre-protocol
placebo recipients. Dots represent point estimates at given threshold values,
with a grid of thresholds created by segmenting the marker values at COVID-19
endpoints into increments of 0.1. This grid spans from the minimum value of the
marker to the highest value for which there are at least 3 COVID-19 endpoints
with a marker measurement at or above that value. The solid black lines are
obtained by linearly interpolating the grid points. The grey shaded area
indicates pointwise 95% confidence intervals (CIs). The estimates and CIs were
adjusted using the assumption that the true threshold-response vaccine efficacy
is non-decreasing. The upper boundary of the green shaded area is the estimate
of the reverse cumulative distribution function (CDF) of the antibody marker
level in non-naïve per-protocol vaccine recipients. Blue points represent
marker values for individual Omicron COVID-19 endpoints. Analyses adjusted for
baseline risk score. bAb-IgG Spike, anti-Spike IgG binding antibody
concentration; LLOQ, lower limit of quantitation; LOD, limit of detection;
nAb-ID50, 50% inhibitory serum dilution neutralizing antibody titer.</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-CA style='font-size:
11.0pt;line-height:115%;font-family:"Arial",sans-serif;color:black'>Statistical
report:</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-CA style='font-size:
11.0pt;line-height:115%;font-family:"Arial",sans-serif;color:black'>T:\covpn\p3005\analysis\correlates\Part_A_Blinded_Phase_Data\reports\NonparametricThresholdCoRResults\</span><span
lang=EN-CA style='color:black'> </span><span lang=EN-CA style='font-size:11.0pt;
line-height:115%;font-family:"Arial",sans-serif;color:black'>threshold_analysis_sanofi_updated_stage2_2025Apr24.pdf</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-CA style='font-size:
11.0pt;line-height:115%;font-family:"Arial",sans-serif;color:black'>To
reproduce this report, follow instructions at </span><span style='color:black'><a
href="https://github.com/CoVPN/correlates_reporting2/tree/master/cor_threshold/sanofi_stage2"><span
lang=EN-CA style='font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif'>https://github.com/CoVPN/correlates_reporting2/tree/master/cor_threshold/sanofi_stage2</span></a></span><span
style='font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
color:black'>  <span lang=EN-CA>(level 1 reproducibility test passed)</span></span></p>

<p class=MsoNormal style='background:white'><span lang=EN-CA style='font-size:
11.0pt;line-height:115%;font-family:"Arial",sans-serif;color:black'>Collage
mapping</span></p>

<p class=MsoListParagraphCxSpFirst style='text-indent:-.25in;background:white'><span
lang=EN-CA style='font-size:11.0pt;line-height:115%;font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-CA style='font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
color:black'>Panel A: page 76 in </span><span style='font-size:11.0pt;
line-height:115%;font-family:"Arial",sans-serif;color:black'>threshold_analysis_sanofi_updated_stage2_2025Apr24.pdf</span></p>

<p class=MsoListParagraphCxSpMiddle style='text-indent:-.25in;background:white'><span
lang=EN-CA style='font-size:11.0pt;line-height:115%;font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-CA style='font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
color:black'>Panel B: page 117 in </span><span style='font-size:11.0pt;
line-height:115%;font-family:"Arial",sans-serif;color:black'>threshold_analysis_sanofi_updated_stage2_2025Apr24.pdf</span></p>

<p class=MsoListParagraphCxSpMiddle style='text-indent:-.25in;background:white'><span
lang=EN-CA style='font-size:11.0pt;line-height:115%;font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-CA style='font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
color:black'>Panel C: page 82 in </span><span style='font-size:11.0pt;
line-height:115%;font-family:"Arial",sans-serif;color:black'>threshold_analysis_sanofi_updated_stage2_2025Apr24.pdf</span></p>

<p class=MsoListParagraphCxSpLast style='text-indent:-.25in;background:white'><span
lang=EN-CA style='font-size:11.0pt;line-height:115%;font-family:Symbol'>·<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><span
lang=EN-CA style='font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
color:black'>Panel D: page 122 in </span><span style='font-size:11.0pt;
line-height:115%;font-family:"Arial",sans-serif;color:black'>threshold_analysis_sanofi_updated_stage2_2025Apr24.pdf</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-CA style='font-size:
11.0pt;line-height:115%;font-family:"Arial",sans-serif'>&nbsp;</span></p>

<p class=MsoNormal><span style='font-size:11.0pt;line-height:115%;font-family:
"Arial",sans-serif'>Figure 5. Controlled risk of Omicron COVID-19 through 129
days post D43 by (A) D43 anti-Spike IgG Omicron concentration, (B) D43 nAb-ID50
BA.1 titer, (C) fold-rise (D43/D01) anti-Spike IgG Omicron concentration, and
(D) fold-rise (D43/D01) nAb-ID50 BA.1 titer in non-naïve per-protocol (A, blue
line; B, blue line) placebo recipients or non-naïve per-protocol (A, purple
line; B, purple line; C, D) vaccine recipients.</span><span style='font-size:
11.0pt;line-height:115%;font-family:"Arial",sans-serif'> Controlled risk</span><span
style='font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif'> was
estimated using a monotone-constrained nonparametric method with covariate
adjustment (default implementation in the R package <i>vaccine</i> available at
CRAN).</span><span
style='font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif'><sup>44</sup></span><span
style='font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif'> Dotted
lines and shading indicate pointwise 95% CIs. The upper and lower horizontal
gray lines are the overall cumulative incidence of Omicron COVID-19 from 7 to
129&#8201;days post D43 in placebo and vaccine recipients, respectively. The
background kernel density plots are estimates of the distribution of each
antibody marker in non-naïve per-protocol recipients. Analyses adjusted for
baseline risk score, sex, geographic region, and FOI score. AU, arbitrary
units; </span><span style='font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
color:black'>bAb-IgG Spike, anti-Spike IgG binding antibody concentration</span><span
style='font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
color:black'>; </span><span style='font-size:11.0pt;line-height:115%;
font-family:"Arial",sans-serif'>nAb-ID50, 50% inhibitory serum dilution
neutralizing antibody titer.</span></p>

<p class=MsoNormal style='background:white'><span style='font-size:11.0pt;
line-height:115%;font-family:"Arial",sans-serif;color:black'>Statistical reports:</span></p>

<p class=MsoNormal style='background:white'><span style='font-size:11.0pt;
line-height:115%;font-family:"Arial",sans-serif;color:black'>T:\covpn\p3005\analysis\correlates\Part_A_Blinded_Phase_Data\reports\ControlledRiskVEResults\</span><span
style='color:black'> </span><span style='font-size:11.0pt;line-height:115%;
font-family:"Arial",sans-serif;color:black'>2025-04-18 Controlled Risk TS2 M5
(Cox + NP).pdf</span></p>

<p class=MsoNormal style='background:white'><span style='font-size:11.0pt;
line-height:115%;font-family:"Arial",sans-serif;color:black'>T:\covpn\p3005\analysis\correlates\Part_A_Blinded_Phase_Data\reports\ControlledRiskVEResults\</span><span
style='color:black'> </span><span style='font-size:11.0pt;line-height:115%;
font-family:"Arial",sans-serif;color:black'>2025-04-18 Controlled Risk V+P TS2
M5 (NP).pdf</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-CA style='font-size:
11.0pt;line-height:115%;font-family:"Arial",sans-serif;color:black'>T:\covpn\p3005\analysis\correlates\Part_A_Blinded_Phase_Data\reports\ControlledRiskVEResults\</span><span
lang=EN-CA style='color:black'> </span><span lang=EN-CA style='font-size:11.0pt;
line-height:115%;font-family:"Arial",sans-serif;color:black'>2025-04-18
Controlled Vaccine Efficacy TS2 M5 (Cox + NP).pdf</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-CA style='font-size:
11.0pt;line-height:115%;font-family:"Arial",sans-serif;color:black'>To
reproduce this report, follow instructions at </span><span style='color:black'><a
href="https://github.com/Avi-Kenny/Code__IC-Pipeline/blob/main/README.md#sanofi-stage-2-correlates-manuscript">https://github.com/Avi-Kenny/Code__IC-Pipeline/blob/main/README.md<span
lang=EN-CA style='font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif'>#sanofi-stage-2-correlates-manuscript</span></a></span><span
style='font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
color:black'> <span lang=EN-CA>(level 1 reproducibility test passed)</span></span></p>

<p class=MsoNormal style='background:white'><span lang=EN-CA style='font-size:
11.0pt;line-height:115%;font-family:"Arial",sans-serif;color:black'>Collage
mapping</span></p>

<p class=MsoNormal style='margin-bottom:4.0pt;background:white'><span
lang=EN-CA style='font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
color:black'>Panel A: page 8 in 2025-04-18 Controlled Risk V+P TS2 M5 (NP).pdf</span></p>

<p class=MsoNormal style='margin-bottom:4.0pt;background:white'><span
lang=EN-CA style='font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
color:black'>Panel B: page 12 in 2025-04-18 Controlled Risk V+P TS2 M5 (NP).pdf</span></p>

<p class=MsoNormal style='margin-bottom:4.0pt;background:white'><span
lang=EN-CA style='font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
color:black'>Panel C: page 23 in 2025-04-18 Vax only Controlled Risk TS2 M5
(Cox + NP).pdf </span></p>

<p class=MsoNormal style='margin-bottom:4.0pt;background:white'><span
lang=EN-CA style='font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
color:black'>Panel D: page 27 in 2025-04-18 Vax only Controlled Risk TS2 M5
(Cox + NP).pdf</span></p>

</div>

<span lang=EN-CA style='font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif'><br
clear=all style='page-break-before:always'>
</span>

<div class=WordSection2>

<p class=MsoListParagraph style='background:white'><span lang=EN-CA
style='font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
color:black'>Final formatted plots for the manuscript from the above reports
(harmonizing y-axis ranges and with Cox curves removed from the “Cox + NP”
plots above):</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-CA style='font-size:
11.0pt;line-height:115%;font-family:"Arial",sans-serif'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpFirst style='background:white'><span lang=EN-CA
style='font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
color:black'>T:\covpn\p3005\analysis\correlates\Part_A_Blinded_Phase_Data\reports\ControlledRiskVEResults\FinalResultsMay23_2025</span></p>

<p class=MsoListParagraphCxSpMiddle style='background:white'><span lang=EN-CA
style='font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
color:black'>plot_risk_5c.pdf</span></p>

<p class=MsoListParagraphCxSpMiddle style='background:white'><span lang=EN-CA
style='font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
color:black'>plot_risk_5d.pdf </span></p>

<p class=MsoListParagraphCxSpMiddle style='background:white'><span lang=EN-CA
style='font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
color:black'>plot_risk_S28c.pdf </span></p>

<p class=MsoListParagraphCxSpMiddle style='background:white'><span lang=EN-CA
style='font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
color:black'>plot_risk_S28d.pdf</span></p>

<p class=MsoListParagraphCxSpMiddle style='background:white'><span lang=EN-CA
style='font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
color:black'>plot_risk_S29c.pdf </span></p>

<p class=MsoListParagraphCxSpMiddle style='background:white'><span lang=EN-CA
style='font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
color:black'>plot_risk_S29d.pdf </span></p>

<p class=MsoListParagraphCxSpMiddle style='background:white'><span lang=EN-CA
style='font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
color:black'>plot_vp_5a.pdf </span></p>

<p class=MsoListParagraphCxSpMiddle style='background:white'><span lang=EN-CA
style='font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
color:black'>plot_vp_5b.pdf </span></p>

<p class=MsoListParagraphCxSpMiddle style='background:white'><span lang=EN-CA
style='font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
color:black'>plot_vp_S28a.pdf</span></p>

<p class=MsoListParagraphCxSpMiddle style='background:white'><span lang=EN-CA
style='font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
color:black'>plot_vp_S28b.pdf</span></p>

<p class=MsoListParagraphCxSpMiddle style='background:white'><span lang=EN-CA
style='font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
color:black'>plot_vp_S29a.pdf</span></p>

<p class=MsoListParagraphCxSpMiddle style='background:white'><span lang=EN-CA
style='font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
color:black'>plot_vp_S29b.pdf</span></p>

<p class=MsoListParagraphCxSpMiddle style='background:white'><span lang=EN-CA
style='font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpLast style='background:white'><span lang=EN-CA
style='font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif'>&nbsp;</span></p>

<p class=MsoNormal style='background:white'><span lang=EN-CA style='font-size:
11.0pt;line-height:115%;font-family:"Arial",sans-serif'>&nbsp;</span></p>

<p class=MsoNormal><span style='font-size:11.0pt;line-height:115%;font-family:
"Arial",sans-serif'>&nbsp;</span></p>

<p class=MsoNormal><span style='font-size:11.0pt;line-height:115%;font-family:
"Arial",sans-serif'>&nbsp;</span></p>

</div>

</body>

</html>
